论文部分内容阅读
目的 研究重组 ＩＬ－ ２（ｒＩＬ－２）和 γ－ＩＦＮ对晚期肝癌患者淋巴细胞粘附肿瘤细胞能力的影响。方法 晚期肝癌患者２４例，用 ｒＩＬ－２和 γ－ＩＦＮ预培养患者外周血淋巴细胞 ４ｈ，采用肿瘤淋巴细胞花环试验测定淋巴细胞粘附肿瘤细胞直接接触效应与活性．结果 ｒＩＬ－２对正常人和肝癌患者的淋巴细胞免疫粘附肿瘤能力都有明显的的提升效应，但单独使用 ｒＩＬ－２对肝癌患者淋巴细胞免疫粘附肿瘤细胞的提升效应较差，ｒＩＬ－２与γ－ＩＦＮ联合使用可显著增强淋巴细胞对肿瘤细胞的免疫粘附功能．结论 肝癌患者淋巴细胞免疫粘附肿瘤细胞能力明显低下，ｒＩＬ－２与γ－ＩＦＮ联合使用具有协同刺激肝癌患者淋巴细胞活性之作用．
Objective To investigate the effect of recombinant IL-2 (rIL-2) and γ-IFN on the ability of lymphocytes to adhere to tumor cells in patients with advanced liver cancer. Methods Twenty-four patients with advanced hepatocellular carcinoma (HCC) were treated with rIL-2 and γ-IFN, and the peripheral blood lymphocytes were pre-cultured for 4 hours. Tumor lymphocyte rosette assay was used to determine the direct contact effect and activity of lymphocyte adhesion tumor cells. Results Both rIL-2 and IL-2 could significantly enhance the ability of lymphocyte immune adherence to normal and hepatocellular carcinoma patients. However, the effect of rIL-2 alone on lymphocyte immunoadsorption of tumor cells in liver cancer patients was poor. The level of rIL- 2 combined with γ-IFN can significantly enhance the immune function of lymphocytes to tumor cells. Conclusion The ability of lymphocytes to adhere to tumor cells in patients with hepatocellular carcinoma is remarkably low. The combination of rIL-2 and γ-IFN can stimulate the activity of lymphocytes in patients with hepatocellular carcinoma.